Project Grant R01CA311472
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $646K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $706,739 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with a completion date of May 31, 2031. This award supports fundamental research to unravel the molecular mechanisms underlying immunotherapy-associated myocarditis (ICI-myocarditis), a severe cardiac inflammation that can occur as a side effect of immune checkpoint inhibitor (ICI) cancer...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $688,073 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds computational research to reconstruct the evolutionary history of cancer metastases, led by Principal Investigator Dr. Peter Van Loo. The project develops novel molecular archeology of cancer approaches—computational methods that leverage DNA sequencing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $2.46 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, to support the INHANCE (Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery) initiative. This five-year project, concluding July 31, 2030, will develop advanced imaging and computational image analysis methodologies to predict, detect, prevent, and manage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a Project Grant of $1,847,485 under the Cancer Treatment Research program (CFDA 93.395) to advance next-generation CAR-NK (chimeric antigen receptor-engineered natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025, with completion targeted for August 31, 2029, funds a clinical trial developing IC9/CAR5-28Z/IL-15...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $621,632 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Treatment Research program (CFDA 93.395) to investigate disulfidptosis, a previously unexplored form of regulated cell death in cancer therapy. The award, initiated June 17, 2026, and scheduled for completion May 31, 2031, supports research to elucidate the molecular and metabolic mechanisms underlying disulfidptosis in...